Navigation Links
MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
Date:2/2/2009

VALENCIA, Calif., Feb. 2 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference on Monday, February 9, 2009 at 2:15 PM (EST) at the Hilton Waldorf Astoria in New York City. In addition to this presentation, the Company will host a breakfast meeting for invited investors and analysts at 7:30 AM (EST) on February 10th.

Interested parties can access links to live webcasts of both presentations from the News & Events section of the Company's website at http://www.mannkindcorp.com. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in Phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes. MannKind maintains a website at https://www.mannkindcorp.com to which MannKind regularly posts copies of its press release as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to email alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.


'/>"/>
SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
2. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
3. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
4. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
5. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
6. MannKind to Present at the UBS Global Life Sciences Conference
7. MannKind Corporation Reports Second Quarter Financial Results
8. MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
9. MannKind to Present at Upcoming Conferences
10. MannKind Corporation Reports First Quarter Financial Results
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... ... firm today announced that LI-COR is moving its B2B sales into the Cloud with the ... ... Consulting , a leading technology services firm today announced that LI-COR is moving its B2B ...
... The University of Georgia Research Foundation, Inc. (UGARF) and ... non-exclusive license for a portfolio of glow-in-the-dark pigments that ... of the visible spectrum for nearly a day. ... Phosphorescence is a process in which energy ...
... , BETHESDA, Md., Aug. 17 Spherix Incorporated (Nasdaq: ... of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, ... , Recent and Upcoming Company Highlights , ... , Clinical trials on Naturlose ...
Cached Biology Technology:Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 2Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud" 3UGA, UPR grant license for long-persistence glow materials, in any color 2UGA, UPR grant license for long-persistence glow materials, in any color 3UGA, UPR grant license for long-persistence glow materials, in any color 4Spherix Reports Second Quarter 2009 Earnings 2Spherix Reports Second Quarter 2009 Earnings 3Spherix Reports Second Quarter 2009 Earnings 4Spherix Reports Second Quarter 2009 Earnings 5Spherix Reports Second Quarter 2009 Earnings 6Spherix Reports Second Quarter 2009 Earnings 7Spherix Reports Second Quarter 2009 Earnings 8
(Date:4/24/2014)... April 24, 2014D-ribose is a commercially important sugar ... as a starting compound for synthesizing riboflavin and ... coli to increase the bacteria,s ability to ... more efficient industrial-scale production of this valuable chemical, ... Biotechnology , a peer-reviewed journal from Mary Ann ...
(Date:4/24/2014)... Society of America (ESA) is very pleased to announce ... of Insect Science from the University of Wisconsin. ... is an international, open-access, peer-reviewed journal that publishes ... and other arthropods -- from the molecular to the ... impacts. It is freely available to individuals and institutions, ...
(Date:4/24/2014)... and the University of North Carolina at Chapel Hill ... identify arterial plaque that is at high risk of ... At issue is the plaque that builds up in ... deemed "vulnerable," meaning that they are more likely to ... or stroke. , "Existing state-of-the-art technologies are capable of ...
Breaking Biology News(10 mins):ESA to publish the Journal of Insect Science 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... in how organisms grow and flourish, but studying their ... difficult. Now, a team of chemists and neurobiologists led ... Erin M. Schuman at the California Institute of Technology ... protein synthesis in specific locations. , The new method, ...
... at the University of Chicago show how the bacteria that ... how, by slightly altering one of the microbe's tools, the ... vaccine. , Both papers -- one published online July 28 ... Infection and Immunity -- focus on aspects of the type-III ...
... greatly benefit crop plants, scientists have deciphered the genome ... from diseases. , The research provides clues to better ... safeguards roots and seeds from infection by harmful microbes ... published in Nature Biotechnology and was scheduled to be ...
Cached Biology News:Protein synthesis can be controlled by light, opening way for new scientific, medical applications 2Protein synthesis can be controlled by light, opening way for new scientific, medical applications 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4Genome study of beneficial microbe may help boost plant health 2
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
...
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Certified U.S. origin. Bovine Serum:, *Certified U.S. origin. Available raw, nonsterile filtered, or sterile filtered. , , *Sterility tested , , *Low Hemoglobin levels , , *Mycoplasma testing upon...
Biology Products: